Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries presented new ILUMYA (tildrakizumab-asmn) clinical insights at the 2019 American Academy of Dermatology (AAD) Annual Meeting, including long-term data showing sustained skin clearance in some
patients living with moderate-to-severe plaque psoriasis after three years of ongoing treatment with ILUMYA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
